Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinoma

• DOI: 10.1186/s12894-022-01139-9
• Publication Date: 2022-11-09T21:22:12Z
• Authors: Kazuma Sugimoto; Satoru Taguchi; Kenjiro Kishitani; Taketo Kawai; Kazuki Masuda; Yu Nakamura; Manami Kinjo; Mitsuhiro Tambo; Jimpei Miyakawa; Yoshiyuki Akiyama; Yuta Yamada; Yusuke Sato; Daisuke Yamada; Tohru Nakagawa; Hiroshi Fukuhara; Haruki Kume
• Keywords: Carboplatin; Regimen

While gemcitabine/cisplatin (GC) is the gold standard regimen for patients with advanced urothelial carcinoma (aUC), either dose-reduced GC or gemcitabine/carboplatin (GCa) an alternative option "cisplatin-unfit" patients. However, few studies have compared outcomes these commonly used regimens in real-world setting.We retrospectively reviewed aUC who received full-dose GC, GCa as first-line salvage chemotherapy at two university hospitals between 2016 and 2020. Progression-free survival, cancer-specific overall well best response adverse event profiles, were among three regimens.Of 105 patients, 41, 27, 37 GCa, respectively. Significant differences noted patients' baseline age, primary site, renal function regimens. Sixty-nine (65.7%) died during a median follow-up period of 14 months. There was no significant difference all survival response. complete rate (2/27, 7.4%) appeared inferior to that (9/41, 22.0%) (6/37, 16.2%). Regarding observed regimens, except significantly fewer cases elevated alanine aminotransferase group other groups.This study oncological toxicological aUC. Unlike clinical trial setting, there almost